PepGen (PEPG) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
PepGen (PEPG) has outperformed Sionna Therapeutics (SION) over the past year, losing 46.8% versus a loss of 87.8%. PepGen is the larger company by market cap ($179.8 million vs $175.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | SION |
|---|---|---|
| Share price | $2.60 | $3.89 |
| Market cap | $179.84M | $175.63M |
| 1-day change | +2.77% | -4.66% |
| YTD return | -60.06% | -90.54% |
| 1-year return | -46.83% | -87.82% |
| EPS (TTM) | $-1.01 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-89.66M | $-75.27M |
| 52-week high | $7.80 | $54.97 |
| 52-week low | $1.31 | $3.78 |
| Distance from 52-week high | -66.67% | -92.92% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +291.92% | +439.85% |
| Average volume | 864.38K | 2.22M |
| Shares outstanding | 69.17M | 45.15M |
| Employees | 57 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed SION by 41.0 percentage points over the past year.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
PEPG vs SION FAQ
Which is bigger, PepGen or Sionna Therapeutics?
PepGen (PEPG) is larger, with a market capitalization of $179.84M compared with $175.63M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, PEPG or SION?
PEPG returned -46.83% over the past 12 months, compared with -87.82% for SION (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.